Literature DB >> 16797832

GPX1 Pro198Leu polymorphism, interactions with smoking and alcohol consumption, and risk for lung cancer.

Ole Raaschou-Nielsen1, Mette Sørensen, Rikke D Hansen, Kirsten Frederiksen, Anne Tjønneland, Kim Overvad, Ulla Vogel.   

Abstract

We genotyped blood samples from 432 lung cancer cases and 798 persons in a comparison group and examined the role of the GPX1 (Pro198Leu, rs1050450) polymorphism and interactions with external exposures in the development of lung cancer. The incidence rate ratio for lung cancer was 0.60 (95% confidence interval: 0.35-1.05) when homozygous carriers of the variant allele were compared with the homozygous carriers of the wild type, and the risk for lung cancer was significantly lower among participants carrying more variant alleles (p-trend=0.03). We found stronger associations between several smoking variables and alcohol intake and lung cancer risk among GPX1(TT) carriers than among GPX1(CC) and GPX1(CT) carriers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16797832     DOI: 10.1016/j.canlet.2006.05.006

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  26 in total

1.  The Mn-superoxide dismutase single nucleotide polymorphism rs4880 and the glutathione peroxidase 1 single nucleotide polymorphism rs1050450 are associated with aging and longevity in the oldest old.

Authors:  Mette Soerensen; Kaare Christensen; Tinna Stevnsner; Lene Christiansen
Journal:  Mech Ageing Dev       Date:  2009-02-05       Impact factor: 5.432

2.  Age specific responses to acute inhalation of diffusion flame soot particles: cellular injury and the airway antioxidant response.

Authors:  Laura S Van Winkle; Jackie K W Chan; Donald S Anderson; Benjamin M Kumfer; Ian M Kennedy; Anthony S Wexler; Christopher Wallis; Aamir D Abid; Katherine M Sutherland; Michelle V Fanucchi
Journal:  Inhal Toxicol       Date:  2010-10-21       Impact factor: 2.724

3.  Genetic variants of MnSOD and GPX1 and susceptibility to bladder cancer in a Turkish population.

Authors:  Canan Kucukgergin; Oner Sanli; Akın S Amasyalı; Tzevat Tefik; Sule Seckin
Journal:  Med Oncol       Date:  2011-09-09       Impact factor: 3.064

Review 4.  Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities.

Authors:  Edith Lubos; Joseph Loscalzo; Diane E Handy
Journal:  Antioxid Redox Signal       Date:  2011-04-10       Impact factor: 8.401

5.  GPx-1 polymorphism (rs1050450) contributes to tumor susceptibility: evidence from meta-analysis.

Authors:  Jiawei Chen; Qiang Cao; Chao Qin; Pengfei Shao; Yilong Wu; Meilin Wang; Zhengdong Zhang; Changjun Yin
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-13       Impact factor: 4.553

6.  Glutathione peroxidase 1 (GPX1) genetic polymorphism, erythrocyte GPX activity, and prostate cancer risk.

Authors:  Zorica Arsova-Sarafinovska; Nadica Matevska; Ayse Eken; Daniel Petrovski; Saso Banev; Sonja Dzikova; Vladimir Georgiev; Aleksandar Sikole; Onur Erdem; Ahmet Sayal; Ahmet Aydin; Aleksandar J Dimovski
Journal:  Int Urol Nephrol       Date:  2008-06-19       Impact factor: 2.370

Review 7.  Molecular mechanisms by which selenoproteins affect cancer risk and progression.

Authors:  Pin Zhuo; Alan M Diamond
Journal:  Biochim Biophys Acta       Date:  2009-03-13

8.  GPX1 gene Pro200Leu polymorphism, erythrocyte GPX activity, and cancer risk.

Authors:  Zhiqiang Hong; Changwei Tian; Xingliang Zhang
Journal:  Mol Biol Rep       Date:  2012-10-17       Impact factor: 2.316

9.  CAT C-262T and GPX1 Pro198Leu polymorphisms in a Turkish population.

Authors:  H Sinan Suzen; Emel Gucyener; Ozgul Sakalli; Zuhal Uckun; Gulcin Kose; Duygu Ustel; Yalcin Duydu
Journal:  Mol Biol Rep       Date:  2009-05-08       Impact factor: 2.316

10.  Association between GPx1 Pro198Leu polymorphism, GPx1 activity and plasma selenium concentration in humans.

Authors:  E Jablonska; J Gromadzinska; E Reszka; W Wasowicz; W Sobala; N Szeszenia-Dabrowska; P Boffetta
Journal:  Eur J Nutr       Date:  2009-05-05       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.